Leukemia Research
Volume 28, Issue 12 , Pages 1303-1312 , December 2004

Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts

  • Jianlin Gong

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-414-1715; fax: +1-617-414-1784.
    • ,
  • Shigeo Koido

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Yoko Kato

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Yasuhiro Tanaka

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Dongshu Chen

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Anna Jonas

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Ilene Galinsky

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Daniel DeAngelo

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • David Avigan

      Affiliations

    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Donald Kufe

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Richard Stone

      Affiliations

    • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

Received 22 December 2003 ,Accepted 30 March 2004.

References 

  1. Richman SP, Gutterman JU, Hersh EM. Cancer immunotherapy. Can Med. Assoc. J. 1979;120:322–324
  2. Bartlett GL, Kreider JW, Purnell DM. Active specific immunotherapy of murine leukemia. Part I. Irradiated tumor cell vaccine. Int. J. Cancer. 1979;24:629–635
  3. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 1995;182:255–260
  4. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. 1989;169:1255–1264
  5. Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin Invest. 1994;94:797–807
  6. Bjorck P. Development of dendritic cells and their use in tumor therapy. Clin Immunol. 1999;92:119–127
  7. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, et al.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 1994;180:1849–1860
  8. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000;18:245–273
  9. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J. Clin Invest. 1992;90:229–237
  10. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood. 1994;84:3054–3062
  11. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood. 1999;94:2048–2055
  12. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, et al.  Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780–786
  13. Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DF. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit. Rev. Immunol. 1998;18:121–131
  14. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur. J. Immunol. 1999;29:2567–2578
  15. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, et al.  Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 2002;62:2861–2868
  16. Severson RK, Ross JA. The causes of acute leukemia. Curr. Opin. Oncol. 1999;11:20–24
  17. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl. J. Med. 1999;341:1051–1062
  18. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 2001;94:459–473
  19. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, et al.  Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 1999;5:823–827
  20. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 1998;16:364–369
  21. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of anti-tumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 2000;165:5713–5719
  22. Mandl CW, Aberle JH, Aberle SW, Holzmann H, Allison SL, Heinz FX. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med. 1998;4:1438–1440
  23. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996;184:465–472
  24. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 1996;183:283–287
  25. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297–1302
  26. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 1996;183:317–322
  27. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998;4:328–332
  28. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I—restricted CTLs. Nature. 1998;392:86–89
  29. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997;3:558–561
  30. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, et al.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 1998;95:6279–6283
  31. Celluzzi CM, Falo LD. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 1998;160:3081–3085
  32. Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans K, van Meirvenne S, et al.  Dendritic cells fused with mastocytoma cells elicit therapeutic anti-tumor immunity. Int. J. Cancer. 1998;76:250–258
  33. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 1998;161:5516–5524
  34. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model. J. Immunother. 2001;24:106–113
  35. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive anti-tumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol. 2001;36:764–771
  36. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 2001;50:337–344
  37. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, et al.  Activation of anti-tumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 2000;97:2715–2718
  38. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, et al.  Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce anti-tumor immunity. J. Immunol. 2000;165:1705–1711
  39. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, et al.  Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int. J. Cancer. 2000;85:618–626
  40. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 2002;51:299–310
  41. Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 2002;168:2111–2117
  42. Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances anti-tumor immunity. Leuk. Res. 2002;26:757–763
  43. Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, et al.  A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat. Med. 2003;9:1215–1219
  44. Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur. J. Clin Invest. 2003;33:897–904
  45. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, et al.  Mediators of innate immunity that target immature, but not mature, dendritic cells induce anti-tumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 2001;167:6644–6653

PII: S0145-2126(04)00125-0

doi: 10.1016/j.leukres.2004.03.018

Leukemia Research
Volume 28, Issue 12 , Pages 1303-1312 , December 2004

Article Tools

* Image Usage & Resolution